Analgesic efficacy of preoperative parecoxib sodium in an orthopedic pain model

Journal of the American Podiatric Medical Association

Volumn 94, Issue 3, 2004, Pages 305-314

  Desjardins, Paul J ^a,b   Traylor, Louise ^b   Hubbard, Richard C ^b  

^a Premier Research   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARECOXIB;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; ANALGESIA; ARTICLE; BLEEDING; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PODIATRY; POSTOPERATIVE PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT WITHDRAWAL; TREMOR; VOMITING;

EID: 2642549671     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/0940305     Document Type: Article

References (38)

1. MOORE PA, WERTHER JR, SELDIN EB, ET AL: Analgesic regimens for third molar surgery: pharmacologic and behavioral considerations. J Am Dent Assoc 113: 739, 1986.
2. NEUMANN S, DOUBELL TP, LESLIE T, ET AL: Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 384: 360, 1996.
3. SAMAD TA, MOORE KA, SAPIRSTEIN A, ET AL: Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471, 2001.
4. WRIGHT A: Recent concepts in the neurophysiology of pain. Man Ther 4: 196, 1999.
5. KATZ J, KAVANAGH BP, SANDLER AN, ET AL: Preemptive analgesia: clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 77: 439, 1992.
6. DESJARDINS PJ, SHU VS, RECKER DP, ET AL: A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 97: 565, 2002.
7. EBERSON CP, PACICCA DM, EHRLICH MG: The role of ketorolac in decreasing length of stay and narcotic complications in the postoperative pediatric orthopaedic patient. J Pediatr Orthop 19: 688, 1999.
8. REINHART DJ, STAGG KS, WALKER KG, ET AL: Postoperative analgesia after peripheral nerve block for podiatric surgery: clinical efficacy and chemical stability of lidocaine alone versus lidocaine plus ketorolac. Reg Anesth Pain Med 25: 506, 2000.
9. SERPELL MG, ANDERSON E, WILSON D, ET AL: I.v. regional diamorphine for analgesia after foot surgery. Br J Anaesth 84: 95, 2000.
10. SOULIER SM, PAGE JC, LARSEN LC, ET AL: The efficacy of ANSAID (flurbiprofen) as an analgesic in foot surgery. J Foot Ankle Surg 36: 414, 1997.
11. SMITH WL, GARAVITO RM, DEWITT DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157, 1996.
12. KUJUBU DA, FLETCHER BS, VARNUM BC, ET AL: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866, 1991.
13. RAZ A, WYCHE A, NEEDLEMAN P: Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci U S A 86: 1657, 1989.
14. XIE WL, CHIPMAN JG, ROBERTSON DL, ET AL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 88: 2692, 1991.
15. KUEHL FA, EGAN RW: Prostaglandins, arachidonic acid, and inflammation. Science 210: 978, 1980.
16. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232, 1971.
17. WEISSMANN G: The actions of NSAIDs. Hosp Pract (Off Ed) 26: 60, 1991.
18. MASFERRER JC, ZWEIFEL BS, MANNING PT, ET AL: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 91: 3228, 1994.
19. SEIBERT K, ZHANG Y, LEAHY K, ET AL: Pharmacological and biochemical demonstration of the role of cyclooxygenase (COX)-2 in inflammation and pain. Proc Natl Acad Sci U S A 91: 12013, 1994.
20. GARCIA-RODRIGUEZ LA, JICK H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769, 1994.
21. CHANEY MA: Side effects of intrathecal and epidural opioids. Can J Anaesth 42: 891, 1995.
22. BUCKLEY MMT, BROGDEN RN: Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 39: 86, 1990.
23. GILLIS JC, BROGDEN RN: Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 53: 139, 1997.
24. STROM BL, BERLIN JA, KINMAN JL, ET AL: Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA 275: 376, 1996.
25. FELDMAN HI, KINMAN, JL, BERLIN JA, ET AL: Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 126: 193, 1997.
26. CHOO V, LEWIS S: Ketorolac doses reduced. Lancet 342: 109, 1993.
27. KARIM A, LAURENT A, SLATER ME, ET AL: A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 41: 1111, 2001.
28. TALLEY JJ, BROWN DL, CARTER JS, ET AL: 4-[5-Methyl-3-phenylisoxazol-4-yl] -benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43: 775, 2000.
29. TALLEY JJ, BERTENSHAW SR, BROWN DL, ET AL: N-[[(5-methyl-3- phenylisoxazol-4-yl)-phenyl]sulfonyl] propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 43: 1661, 2000.
30. KUSS M, MEHLISCH D, BAUMAN A, ET AL: Analgesic activity of single IV doses of parecoxib, a COX-2 specific inhibitor, and Toradol® in postoperative dental pain [abstract]. Presented at the Ninth World Congress on Pain, August 22-27, 1999, Vienna.
31. MEHLISCH D, KUSS M, BAUMAN A, ET AL: Onset and duration of analgesia of single IM doses of parecoxib, a COX-2 specific inhibitor, in postoperative dental pain [abstract]. Presented at the Ninth World Congress on Pain, August 22-27, 1999, Vienna.
32. HUBBARD RC, KUSS ME, DANIELS ST: Parecoxib, a new parenteral COX-2 selective inhibitor with an enhanced analgesic profile. Paper presented at the World Pain Congress, July 15-21, 2000, San Francisco.
33. NOVECK RJ, LAURENT A, KUSS ME, ET AL: Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomized, controlled trials. Clin Drug Invest 21: 465, 2001.
34. NOVECK RJ, KUSS ME, QIAN J, ET AL: Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect heparin-regulated blood coagulation parameters [abstract]. Presented at the Twenty-sixth Annual Meeting of the American Society of Anesthesia and Regional Pain Medicine, May 10-13, 2001, Vancouver.
35. DESJARDINS PJ, GROSSMAN EH, Kuss ME, ET AL: The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg 93: 721, 2001.
36. Guidance for Industry, "Good Clinical Practice: Consolidated Guidance," International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use (ICH), Federal Register 62 (May 9, 1997).
37. MILLER RG: Survival Analysis, John Wiley & Sons, New York, 1981.
38. SIMON R, LEE YJ: Nonparametric confidence limits for survival probabilities and medium survival times. Cancer Treat Rep 66: 37, 1982.